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ABSTRACT 69 
Objective: This study aimed to develop a novel therapeutic vaccine based on a 70 
unique B cell epitope and investigate its therapeutic potential against chronic hepatitis 71 
B (CHB) in animal models. 72 
Methods: A series of peptides and carrier proteins were evaluated in HBV-73 
tolerant mice to obtain an optimized therapeutic molecule. The immunogenicity, 74 
therapeutic efficacy and mechanism of the candidate were investigated systematically. 75 
Results: Among the HBsAg-aa119-125-containing peptides evaluated in this 76 
study, HBsAg-aa113-135 (SEQ13) exhibited the most striking therapeutic effects. A 77 
novel immuno-enhanced virus-like particle carrier (CR-T3) derived from the roundleaf 78 
bat HBV core antigen (RBHBcAg) was created and used to display SEQ13, forming 79 
candidate molecule CR-T3-SEQ13. Multiple copies of SEQ13 displayed on the surface 80 
of this particulate antigen promote the induction of a potent anti-HBs antibody 81 
response in mice, rabbits and cynomolgus monkeys. Sera and purified polyclonal IgG 82 
from the immunized animals neutralized HBV infection in vitro and mediated efficient 83 
HBV/HBsAg clearance in the mice. CR-T3-SEQ13-based vaccination induced long-84 
term suppression of HBsAg and HBV DNA in HBV transgenic mice and eradicated the 85 
virus completely in hydrodynamic-based HBV carrier mice. The suppressive effects 86 
on HBsAg were strongly correlated with the anti-HBs level after vaccination, 87 
suggesting that the main mechanism of CR-T3-SEQ13 vaccination therapy was the 88 
induction of a SEQ13-specific antibody response that mediated HBV/HBsAg 89 
clearance. 90 
Conclusions: The novel particulate protein CR-T3-SEQ13 suppressed HBsAg 91 
effectively through induction of a humoral immune response in HBV-tolerant mice. This 92 
B cell epitope-based therapeutic vaccine may provide a novel immunotherapeutic 93 
agent against chronic HBV infection in humans. 94 
Keywords: Hepatitis B virus; therapeutic vaccine; B cell epitope; HBsAg 95 
suppression 96 
  97 
Significance of this study 98 
What is already known on this subject? 99 
 Achievement of HBsAg loss is an ideal endpoint of chronic hepatitis B (CHB) 100 
treatment and it is rarely achieved by current approved anti-HBV drugs. 101 
 High load of HBsAg directly inhibit both adaptive and innate immune functions 102 
and ultimately leads to specific tolerance that prevents the host from eradicating HBV 103 
infection. A long-term suppression of HBsAg hopefully allows for restoration of anti-104 
HBs B cell response and HBV specific T-cell function.  105 
 Most HBV therapeutic vaccines based on the native HBsAg and HBcAg could 106 
induce specific T cells in HBV carrier mice, even in CHB patients, but there was no 107 
significant effective antibody response that mediates viral clearance, thus exhibited 108 
limited inhibitory effect on HBsAg levels. 109 
 The antibodies recognise the sA epitope (HBsAg-aa119-125) exhibit more 110 
remarkable and prolonged HBsAg suppression effects than antibodies binding to other 111 
epitopes as we described previously. 112 
What are the new findings? 113 
 Among the HBsAg-aa119-125-containing peptides evaluated in this study, 114 
HBsAg-aa113-135 (SEQ13) exhibited the most striking therapeutic effects. A novel 115 
immuno-enhanced virus-like particle carrier (CR-T3) derived from the roundleaf bat 116 
HBV core antigen (RBHBcAg) was created and used to display SEQ13, forming the 117 
novel particulate protein CR-T3-SEQ13.  118 
 Multiple copies of SEQ13 displayed on the surface of this particulate antigen 119 
promote the induction of a potent antibody response in mice, rabbits and cynomolgus 120 
monkeys, and dominant antibodies recognize HBsAg-aa119-125, which exhibit broad 121 
spectrum of activity to mediate HBsAg clearance in vivo and neutralize HBV infection 122 
in vitro. 123 
 CR-T3-SEQ13-based vaccination showed a long-term suppression of HBsAg 124 
and HBV DNA in HBV transgenic mice and eradicated the virus completely in 125 
hydrodynamic-based HBV carrier mice, by induction of a SEQ13-specific antibody 126 
response that mediated HBV/HBsAg clearance. 127 
How might it impact on clinical practice in the foreseeable future?  128 
 CR-T3-SEQ13 is a superior candidate based on a unique B cell eiptope for 129 
developing therapeutic vaccine against HBV, which will be tested in the clinic alone or 130 
in combination with current available anti-HBV drugs to treat CHB patients and aims 131 
to increase the HBsAg loss rate.  132 
 If successful, CR-T3-SEQ13-based immunotherapy will provide a novel anti-133 
HBV strategy to achieve long-term inhibition of the HBsAg levels and improve the 134 
clinical management of CHB.  135 
 136 
  137 
INTRODUCTION 138 
Currently, approximately 250-340 million individuals are chronically infected with 139 
hepatitis B virus (HBV), which is one of the most prevalent chronic viral infections 140 
worldwide, and have a 15%-25% risk of dying from HBV-related disease1-3. The 141 
current approved anti-HBV drugs, including nucleoside/nucleotide analogues and 142 
PEG-interferons, can suppress viral replication and limit hepatitis B but cannot reduce 143 
the viral antigen load effectively. Achieving loss of hepatitis B virus surface antigen 144 
(HBsAg) with or without anti-HBs seroconversion, which is the optimal endpoint of 145 
current treatment, is rare4-6. Thus, new antiviral strategies against chronic HBV 146 
infection are urgently required. Why is chronic hepatitis B so difficult to cure? Generally, 147 
there are two major obstacles to overcome. The first obstacle is the stable presence 148 
of covalently closed circular DNA (cccDNA), which is the template for HBV production 149 
and forms a mini-chromosome in the hepatocyte nucleus7. However, the mechanisms 150 
underlying the maintenance and degradation of cccDNA are not fully understood, and 151 
no convincing theory has guided the discovery of drugs targeting cccDNA7. The 152 
second main obstacle is the high HBsAg load, which has been proposed to directly 153 
inhibit both adaptive and innate immune functions and ultimately leads to specific 154 
tolerance that prevents the host from eradicating HBV infection8, 9. Several studies 155 
have indicated that the appearance of immune tolerance to chronic viral infections is 156 
highly associated with the viral antigen load10, 11. Viruses with high viral loads, such as 157 
HBV, HIV, HCV and LCMV, cause a severe loss of T cell numbers and/or functions11. 158 
Furthermore, a high ratio of antigen to antigen-specific B cells can lead to terminal 159 
differentiation of B cells and ultimately loss of effective IgG responses12. Consistently, 160 
prolonged inhibition of the HBsAg level can promote reversal of B cell tolerance to 161 
produce an anti-HBs antibody response13, 14. In HBeAg-negative patients, the lower 162 
HBsAg level predicts a higher probability of achieving HBsAg loss15. HBsAg 163 
seroclearance achieved after therapy has been associated with a significantly lower 164 
hepatocellular carcinoma (HCC) incidence or mortality rate16. These studies indicate 165 
that the HBsAg levels are associated with progression of liver disease. Therefore, the 166 
development of new drugs that can effectively reduce the HBsAg level may restore 167 
specific immune responses and achieve a higher functional cure rate. 168 
Therapeutic vaccine is one of the most promising biologics against chronic viral 169 
infections. However, most therapeutic vaccine candidates designed to induce T cell 170 
responses or based on native HBsAg have missed their primary endpoints in clinical 171 
trials17-22. In the presence of high HBsAg levels in HBV carriers, T cells targeting the 172 
dominant epitopes of HBsAg are believed to be exhausted, which would represent a 173 
big challenge for stimulation of an effective cellular immune response without removal 174 
of the abundant HBsAg. Induction of an anti-HBs antibody response may be one 175 
promising approach to reduce the circulating HBsAg level23. Therefore, we propose 176 
that a functional B cell epitope derived from HBsAg must be found and an 177 
immunogenic virus-like particle (VLP) must be designed to display hundreds copies of 178 
this epitope. A chimeric VLP displaying multiple epitopes will stimulate stronger 179 
epitope-specific antibody responses that can mediate HBsAg clearance in vivo. In our 180 
previous study, we found that not all antibodies against HBsAg demonstrated an equal 181 
ability to clear HBV in vivo; only E6F6-like antibodies recognizing the unique sA 182 
epitope (HBsAg-aa119-125 as the core motif) could potently mediate HBsAg 183 
clearance24-26. Previous findings suggest that the epitope is the key factor that 184 
determines the efficacy of anti-HBsAg antibodies, and the sA epitope has potential to 185 
be a therapeutic target against chronic hepatitis B. On one hand, mAb-based 186 
immunotherapy represents a promising avenue for treatment of chronic hepatitis B; on 187 
the other hand, the sA epitope can be used to develop a novel therapeutic vaccine 188 
that is expected to primarily induce humoral immune responses.  189 
In this study, an optimized peptide (SEQ13, HBsAg-aa113-135) based on the sA 190 
epitope was designed for displaying on the spikes of a novel immuno-enhanced virus-191 
like particle carrier (CR-T3) derived from the roundleaf bat hepatitis B virus core 192 
antigen (RBHBcAg); the candidate molecule was named CR-T3-SEQ13. Multiple 193 
copies of epitopes on the surface of this particulate antigen promote the production of 194 
a potent sA epitope-specific antibody response and then mediate long-term HBsAg 195 
clearance and suppress the viral load in HBV transgenic (HBV-Tg) mice and 196 
hydrodynamic-based HBV (HDI-HBV) carrier mice. We also found good safety and 197 
immunogenicity of CR-T3-SEQ13 in cynomolgus monkeys. Induction of a similar 198 
immune response in chronic hepatitis B patients will represent a promising method to 199 
achieve long-term inhibition of the HBsAg levels and a higher functional cure rate. 200 
 201 
MATERIALS AND METHODS 202 
Animals 203 
The HBV-Tg mice were provided by Pei-Jer Chen (NTU, Taiwan) and bred at the 204 
Laboratory Animal Centre of Xiamen University27; this study used 8-10-week-old HBV-205 
Tg mice. The hydrodynamic injection (HDI)-based HBV carrier models were developed 206 
as previously described using the “B6-Tg(AAVS1)A1Xob/J” strain and the pAAV-207 
HBV1.2 plasmid 28, 29. BALB/c mice (6-8 weeks old) were purchased from Shanghai 208 
Lingchang Biotechnology Co., Ltd. The New Zealand White (NZW) rabbits used for 209 
immunization were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. 210 
All mice were maintained under specific pathogen-free conditions in the Laboratory 211 
Animal Centre of Xiamen University. The experiments in mice and rabbits were 212 
conducted under approval of the Institutional Animal Care and Use Committee at 213 
Xiamen University and were in accordance with the Guide for the Care and Use of 214 
Laboratory Animals. 215 
Four male and 3 female cynomolgus monkeys were used in the immunogenicity 216 
study, which was conducted at WuXi AppTec (Suzhou) Co., Ltd. All experiments in 217 
this study were in full compliance with the protocol and conformed to the following 218 
regulations and guidelines regarding animal care and welfare: AAALAC International 219 
and NIH guidelines as reported in the “Guide for the Care and Use of Laboratory 220 
Animals” and the National Research Council – ILAR, Revised 2011. The study was 221 
reviewed and approved by WuXi AppTec’s Institutional Animal Care and Use 222 
Committee (IACUC) prior to any activities involving animals.  223 
Blood from the chronic Hepatitis B patients 224 
This study used 25 blood samples from hospitalized patients with chronic hepatitis 225 
B. The study was approved by the Medical Ethics Committee of School of Public 226 
Health of Xiamen University. Written informed consent was obtained from all patients. 227 
More details of vaccine preparation, epitope mapping of antibodies, detection of 228 
HBV markers, Cryo-EM and 3D reconstruction of CR-T3-SEQ13, combinational 229 
treatment experiments, in in vivo potency of anti-CR-T3-SEQ13 sera or purified 230 
polyclonal IgG and in vitro neutralizing assay are provided in the online supplementary 231 
materials and methods and supplementary tables. 232 
 233 
RESULTS 234 
Construction of a unique B cell epitope-based virus-like particle vaccine: CR-235 
T3-SEQ13 236 
For a recombinant protein therapeutic vaccine designed to induce an epitope-specific 237 
B cell response, the key factors associated with efficacy include functional epitopes, 238 
immunogenic carriers, and adjuvants. In this study, experiments were performed to 239 
systematically optimize the epitopes and carriers. According to our previous research, 240 
HBsAg-aa119-125 was proposed as an initial target24.  241 
To obtain an optimized epitope, we selected five polypeptides of different lengths 242 
derived from HBsAg that contained HBsAg-aa119-125; then, the coding sequences of 243 
the peptides were inserted into the truncated HBcAg carrier (HBC149) and expressed 244 
in an E. coli system (Supplemental Figure 1A). All five chimeric proteins and the carrier 245 
protein spontaneously assembled into spherical particles with a diameter of 246 
approximately 30 nm, and we obtained high-purity particles displaying these peptides 247 
on the surface (Supplemental Figure 1B). Then, we evaluated the immunogenicity of 248 
these antigens in HBV-free BALB/c mice. The data showed that all five particulate 249 
antigens containing HBsAg-aa119-125 could induce strong anti-HBs and anti-carrier 250 
antibody responses (Supplemental Figure 2A, B), with the HBC149-S113-135-251 
immunized mice showing slightly higher anti-HBs antibody levels than the other groups 252 
(Supplemental Figure 2A). Furthermore, we evaluated the immunogenicity and 253 
efficacy of these antigens in HBV-Tg mice. The results showed that these antigens 254 
could induce strong anti-carrier antibody responses comparable to those of the HBV-255 
free mice (Supplemental Figure 2D), although the anti-HBs antibody response was 256 
significantly weaker, as expected (Supplemental Figure 2C). The highest anti-HBs 257 
antibody levels were detected in the mice after HBC149-S113-135 treatment; 258 
consistently, the HBsAg and HBV DNA levels of this group of mice decreased 259 
significantly compared with those of the other mouse groups (Supplemental Figure 2E, 260 
F). Therefore, we selected HBsAg-aa113-135, which is a 23-amino acid polypeptide, 261 
as an optimal candidate for further study, and we named it SEQ13. 262 
To obtain the optimized carrier, a series of VLP carriers based on viral capsids 263 
were evaluated, including HBcAg carriers with different mutations, a woodchuck 264 
hepatitis B virus core antigen (WHBcAg) carrier, a human papillomavirus (HPV) L1 265 
carrier and bat hepadnavirus capsids. Finally, RBHBcAg, which is the capsid protein 266 
of the intermediate roundleaf bat (Hipposideros larvatus) hepatitis B virus (RBHBV, 267 
NCBI GenBank Accession Number: KC790373.1) was selected as the lead 268 
candidate30. The full-length RBHBcAg consists of 189 amino acids and has a 269 
topological domain similar to that of HBcAg that contains an arginine-rich domain at 270 
the C-terminus. The arginine-rich region binds to host nucleic acids nonspecifically; 271 
thus, RBHBcAg-aa150-189 was truncated to prevent its interference with protein 272 
purification. The truncated carrier, which was named RBHBcAg149, can 273 
spontaneously assemble into VLPs in an E. coli system. In addition to the importance 274 
of particulate shape for immunogenicity, helper T cell responses are also very 275 
important for effective B cell responses, and CD8+ T cell responses are beneficial for 276 
eradication of intracellular viruses. Therefore, we were trying to integrate the well-277 
studied CD4+ T cell epitopes and CD8+ T cell epitopes into the RBHBcAg149 carrier. 278 
We think that the modified molecule containing human T cell epitopes can be used as 279 
candidate molecule by satisfying the following three points: (1) It still has the 280 
characteristics of spontaneous assembly into virus-like particles; (2) It has the 281 
therapeutic effects comparable to or better than CR-SEQ13 in HBV carrier mice, which 282 
indicate that the immunogenicity is not damaged; (3) The selected epitopes can bind 283 
to as many HLA alleles as possible to cover a larger population31. The modified 284 
molecule can enhance the IFNγ releasing in the antigen-stimulated whole blood 285 
culture system derived from chronic hepatitis B patients. The experiments were carried 286 
out for these three points. Finally, one CD8+ T cell epitope and two helper CD4+ T cell 287 
epitopes derived from HBcAg were introduced into RBHBcAg149 by homologous 288 
replacement (Figure 1A), including the CD8+ T cell epitope HBcAg-aa18-27 289 
(FLPSDFFPSV)31, 32 and the CD4+ T cell epitopes HBcAg-aa50-69 290 
(PHHTALRQAILCWGELMTLA)31, 33 and HBcAg-aa120-140 291 
(VSFGVWIRTPPAYRPPNAPIL)31, 34. The sequence of SEQ13 polypeptide and linker 292 
was inserted into modified carrier (CR-T3) by replacement of RBHBcAg-aa79-81 to 293 
form a chimeric molecule with a length of 193 amino acids, designated CR-T3-SEQ13. 294 
We obtained the candidate therapeutic protein with a purity higher than 95% and a 295 
molecular weight of 20.4 kDa after purification by column chromatography (Figure 1B). 296 
This protein could still spontaneously assemble into VLPs (Figure 1C, Supplemental 297 
Figure 3A). We further used cryo-electron microscopy (cryo-EM) and 3D image 298 
reconstruction methods to investigate the structure of CR-T3-SEQ13 VLPs. The 6.3 Å 299 
resolution cryo-EM map revealed a T = 3 icosahedral capsid structure with a diameter 300 
of ~36nm, which was highly similar to HBV core particle35 (Figure 1D). The SEQ13 301 
polypeptide was located on the top of each protrusion (Figure 1D), thus was presumed 302 
to behave potential to elicit strong immune response. The efficacy of CR-T3-SEQ13 303 
and CR-SEQ13 to reduce HBsAg levels were evaluated in both male and female HBV-304 
TG mice. The data showed that the HBsAg decline in CR-T3-SEQ13 treated mice 305 
were comparable with those of CR-SEQ13 (supplemental figure 3B). In addition, we 306 
used IFNγ release assay (IGRA) to test T cell responsiveness to antigens in whole 307 
blood of chronic Hepatitis B patients, the data showed that the level of IFNγ in CR-T3-308 
SEQ13 stimulated blood samples were significantly higher than that of CR-SEQ13 and 309 
the negative control group (supplemental figure 3C). These results suggested that CR-310 
T3-SEQ13 could be used as a candidate molecule for further investigation. 311 
 312 
CR-T3-SEQ13 induces sA epitope-specific antibodies with broad-spectrum 313 
activity to mediate HBsAg clearance 314 
To evaluate whether CR-T3-SEQ13 could induce specific antibodies against 315 
HBsAg, BALB/c mice were used to assess the dose-response relationship. Seven 316 
groups of BALB/c mice were immunized with a vaccine containing a fixed dose of 317 
aluminum adjuvant (126 μg/dose) and variant doses of CR-T3-SEQ13 via 318 
intramuscular injection (0 μg, 0.6 μg, 3 μg, 6 μg, 12 μg, 30 μg and 60 μg). The data 319 
showed that CR-T3-SEQ13 induced a potent HBsAg-specific antibody response. The 320 
antibody titers gradually increased after the booster immunizations, whereas no 321 
specific antibody response was observed in the adjuvant control group (Figure 2A). 322 
The serum anti-HBs antibody titers showed a dose-response relationship at weeks 2, 323 
3, and 4. The antibody levels of the 60-μg group were comparable to those of the 30-324 
μg group, whereas the other dose groups showed lower doses and antibody titers. 325 
The results suggest that a higher antigen dose can induce a stronger and faster 326 
antibody response in the early phase. 327 
To identify the epitopes of antibodies induced by CR-T3-SEQ13 vaccination, both 328 
polyclonal antibodies from the sera and monoclonal antibodies (mAbs) from a mouse 329 
hybridoma were analyzed. The sera were collected from mice, rabbits and cynomolgus 330 
monkeys immunized with CR-T3-SEQ13, and a total of 11 mouse mAbs recognizing 331 
SEQ13 were obtained. Alanine-scanning mutations of SEQ13 were used to identify 332 
key residues for the antibody binding activity. The results showed that all of the 333 
polyclonal antibodies from the three species were sensitive to mutations located in the 334 
HBsAg-aa119-125 region, especially C121 and C124, which are the key amino acids 335 
of the sA epitope recognized by E6F6 (Figure 2B). Among the mAbs, 10 of 11 336 
recognized the HBsAg-aa119-125 region and only one antibody recognized the C-337 
terminus of HBsAg-aa113-135, which was more sensitive to amino acid mutations in 338 
HBsAg-aa126-132 (Figure 2B). The results indicated that the dominant antibodies 339 
induced by CR-T3-SEQ13 were similar to those of E6F6, suggesting that the 340 
antibodies would be able to functionally mediate HBsAg clearance in vivo. 341 
A total of 10 HBV genotypes have been identified worldwide, among which 342 
genotype A, B, C, and D are the most prevalent. To evaluate the broad spectrum anti-343 
HBV effects of polyclonal antibodies induced by CR-T3-SEQ13, sera were collected 344 
from BALB/c mice immunized with CR-T3-SEQ13 and transferred to mice carrying 345 
HBV genotypes A, B, C and D. Blood was collected from the mice at pretreatment (0) 346 
and at 2 and 12 hours posttreatment, and short-term dynamic changes in the HBsAg 347 
levels were monitored. The results showed that the HBsAg levels in the carrier mice 348 
for the four HBV genotypes were rapidly and significantly reduced to very low levels 349 
within 2 hours (Figure 2C). This result shows that the CR-T3-SEQ13-induced 350 
antibodies can effectively suppress the globally predominant HBV genotypes. 351 
 352 
CR-T3-SEQ13 significantly inhibits HBsAg and HBV DNA in HBV-Tg mice in a 353 
dose-dependent manner 354 
HBV-Tg mice were used to evaluate the anti-HBV efficacy of CR-T3-SEQ13 355 
vaccination. To evaluate the relationship between efficacy and the antigen dose, 356 
formulations with three different antigen doses were prepared with 30 μg, 12 μg and 357 
3 μg of CR-T3-SEQ13. The same dose of alum adjuvant without antigen was included 358 
as the control group. Four groups of HBV-Tg mice (4 female and 4 male mice per 359 
group) were intramuscularly injected with 150 μL of the vaccine formulations at 0, 2, 360 
3, 4, 5 and 6 weeks. Compared with those of the control mice treated with adjuvant 361 
alone, significant dose-dependent inhibitory effects on serum HBsAg and HBV DNA 362 
were observed in the CR-T3-SEQ13 treated mice (Figure 3A-D). With the antigen dose 363 
of 30 μg, the average HBsAg level decreased from approximately 4600 IU/mL to 300 364 
IU/mL in the female mice (Figure 3A) and from approximately 14000 IU/mL to 2500 365 
IU/mL in the male mice (Figure 3B), for an inhibition rate of greater than 90%. The 366 
average HBV DNA level decreased from 6.44×106 IU/mL to 7.60×104 IU/mL in the 367 
female mice (Figure 3C) and from 1.10×108 IU/mL to 8.00×105 IU/mL in the male mice 368 
(Figure 3D), for an inhibition rate of 99%. Therefore, the efficacy of the therapeutic 369 
vaccine described in this study was correlated with the CR-T3-SEQ13 antigen dose, 370 
and the higher antigen doses were associated with better inhibitory effects on HBV. 371 
Furthermore, to verify whether different immunization procedures would affect the 372 
vaccine efficacy, two different treatment schedules were tested (0, 2, 3, 4, 5, and 6 373 
weeks and 0, 2, 4, 6, 8, and 10 weeks). Significant inhibition of the HBsAg levels was 374 
achieved by both immunization procedures in the male and female mice, with no 375 
significant differences (Figure 3E, F). We monitored the HBsAg level until 19 weeks 376 
and found that the inhibitory effects were sustained without apparent viral rebound 377 
(Figure 3E, F). The results indicated that the CR-T3-SEQ13-based therapeutic vaccine 378 
could induce specific immune responses and mediate a potent reduction of HBsAg 379 
and HBV DNA in the HBV-Tg mice, which were highly tolerant to HBV. We also 380 
evaluated the anti-HBV effects of a vaccine consisting of recombinant natural HBsAg 381 
plus HBcAg in the HBV-Tg mice, the formulation of which include 12 µg of HBsAg and 382 
12 µg of HBcAg per dose, with alum adjuvant (840µg/mL of aluminium) that is the 383 
same with CR-T3-SEQ13 vaccine. The data showed that no significant decrease in 384 
the HBsAg and HBV DNA levels was observed in mice treated by the HBsAg plus 385 
HBcAg vaccine; in contrast, the viral loads in the CR-T3-SEQ13-treated mice were 386 
suppressed and were significantly lower at the endpoint of treatment (Supplemental 387 
Figure 4). 388 
Furthermore, the intrahepatic HBsAg and HBcAg levels were analyzed by 389 
immunohistochemistry at week 8 posttreatment. The data showed that the cytosolic 390 
HBsAg level in the hepatocytes of the CR-T3-SEQ13-treated mice was much lower 391 
than that in the alum-treated mice (Figure 4A) and that the intrahepatic HBcAg levels 392 
were comparable between the two groups (Figure 4B). We also measured the HBsAg 393 
and HBcAg in liver lysate of these mice quantitatively. The data was consistent with 394 
the observed results of immunohistochemistry. The HBsAg of the CR-T3-SEQ13 395 
treated group was significantly lower than that of the control group, which was about 396 
30% of the control group, and the level of HBcAg was not significantly different 397 
between the two groups (Supplemental Figure 5). This observation was similar to the 398 
intrahepatic anti-HBV effects of E6F6 that we reported previously24. 399 
 400 
CR-T3-SEQ13 vaccination eradicated HBsAg and HBV DNA in hydrodynamic 401 
injection-based HBV carrier mice 402 
To further evaluate the potent ability of CR-T3-SEQ13 to induce an anti-HBs 403 
antibody response and eliminate HBsAg, the HDI-HBV carrier mouse model was used. 404 
HDI-HBV mice have been demonstrated to have acquired immune tolerance to HBV, 405 
which is similar to the situation experienced by most chronic hepatitis B patients who 406 
develop immune tolerance due to HBV exposure at an early age. We developed HDI-407 
HBV mice based on the “B6-Tg(AAVS1)A1Xob/J” strain as described previously 29. 408 
Mice were screened according to the HBsAg level at 6 weeks after hydrodynamic 409 
injection of the pAAV-HBV1.2 plasmid. Mice with HBsAg levels higher than 2000 410 
IU/mL were selected for this study. Ten mice with comparable HBsAg levels were 411 
selected and divided into two groups, which were treated with the CR-T3-SEQ13 412 
vaccine or the alum adjuvant control. A total of five doses were injected at weeks 0, 2, 413 
3, 4 and 5. The data showed that CR-T3-SEQ13 vaccination could induce an anti-HBs 414 
antibody response (Figure 5B) together with a decline in HBsAg to the lower limit of 415 
detection that was sustained at undetectable levels for more than 40 weeks after drug 416 
treatment had ceased. In contrast, mice in the control group still continued to carry 417 
HBsAg, with an average level higher than 100 IU/mL (Figure 5A). The results 418 
suggested that CR-T3-SEQ13 could effectively stimulate the SEQ13-specific antibody 419 
response and then mediate HBsAg clearance, which was similar to the “functional cure” 420 
situation defined as HBsAg loss and/or anti-HBs seroconversion. 421 
 422 
Combinational therapy with CR-T3-SEQ13 plus nucleoside analogues 423 
Nucleoside/nucleotide analogs and interferons are currently approved anti-HBV 424 
drugs. Entecavir (ETV) and Tenofovir disoproxil fumarate (TDF) are first-line oral anti-425 
HBV drugs. The effect of CR-T3-SEQ13 in combination with either ETV or TDF was 426 
investigated. Five groups were designed (ETV alone, TDF alone, RHBPI alone, ETV 427 
plus RHBPI and TDF plus RHBPI). In the combination therapy groups, the vaccination 428 
was followed by two weeks of oral administration of the analogues. The serum HBsAg 429 
level was significantly decreased in the mice treated with CR-T3-SEQ13 plus ETV, 430 
CR-T3-SEQ13 plus TDF or CR-T3-SEQ13 alone (Figure 6A-D). The inhibitory effect 431 
of CR-T3-SEQ13 plus TDF treatment on the serum HBsAg level of the male mice was 432 
slightly better than that of CR-T3-SEQ13 plus ETV or CR-T3-SEQ13 treatment alone 433 
(Figure 6B); in contrast, no obvious change in HBsAg was observed in the mice treated 434 
with ETV or TDF alone (Figure 6A, B). The data suggest that there was no interference 435 
between the first-line anti-HBV nucleoside analogues and CR-T3-SEQ13. TDF may 436 
have the potential to improve the therapeutic effect of CR-T3-SEQ13 in this model.  437 
To analyze the correlation between the anti-SEQ13 antibody titer and the decline 438 
in HBsAg, serum anti-SEQ13 antibodies of all mice were measured by indirect ELISA. 439 
The kinetics of anti-SEQ13 antibody titers indicated that female mice have a stronger 440 
antibody response than male mice (Supplemental Figure 6). The data showed a strong 441 
positive correlation between the HBsAg decline (weeks 0-7) and the anti-SEQ13 442 
antibody titer at week 7 (R2=0.7898, P<0.0001) (Figure 6E). Meanwhile, the HBsAg 443 
level was strongly negatively correlated with the anti-SEQ13 antibody titer at week 7 444 
(R2=0.7427, P<0.0001) (Figure 6F). The strong correlation indicates that the anti-HBV 445 
effects of CR-T3-SEQ13 vaccination are highly dependent on the induction of an anti-446 
SEQ13 antibody response, which is consistent with our hypothesis. 447 
 448 
Immunogenicity of CR-T3-SEQ13 in Cynomolgus Monkeys  449 
The immunogenicity of alum-adjuvanted CR-T3-SEQ13 and the time course of 450 
the immune response were evaluated in cynomolgus monkeys. Seven cynomolgus 451 
monkeys were used in this study. The immunization schedule was 6 injections over 452 
the time course of 0, 2, 6, 10, 14 and 18 weeks. Venous blood was collected every 2 453 
weeks out to 26 weeks to monitor the dynamics of the antibody response. The HBsAg-454 
specific antibody titer increased significantly and reached a plateau at 6 weeks 455 
following the 3 injections (Figure 7A). The peak response occurred at 8 weeks, with 456 
an anti-HBs antibody titer of approximately 14,800 mIU/mL; human hepatitis B 457 
immunoglobulin (HBIG) was used as the active standard (Figure 7A). This result 458 
indicated that CR-T3-SEQ13 had good immunogenicity in cynomolgus monkeys. 459 
 460 
Potency of the anti-HBV polyclonal antibodies induced by CR-T3-SEQ13 461 
To evaluate the in vitro neutralizing activity of the anti-HBs antibodies induced by 462 
CR-T3-SEQ13 in cynomolgus monkeys, HepG2 cells stably expressing human Na+-463 
taurocholate cotransporting polypeptide (NTCP) (named the HepG2-hNTCP-2B1 cell 464 
line) were used. Cynomolgus monkey sera collected at 12 weeks from vaccinated 465 
monkeys were used as the test sample, and HBIG (1 IU/mL) was used as a control. A 466 
two-fold serum dilution series was prepared from 1/10 to 1/10240. The polyclonal 467 
antibodies from the monkeys immunized with CR-T3-SEQ13 showed good 468 
neutralization activity comparable with that of 1 IU/mL of HBIG (Figure 7B). Generally, 469 
good protective effects can be achieved if the anti-HBs titer is above 10 mIU/mL, 470 
suggesting that the antibodies generated by CR-T3-SEQ13 have protective effects 471 
and thus may play a role in protection of HBV-free hepatocytes from HBV infection or 472 
block the spread of HBV in the liver. 473 
To further evaluate the in vivo anti-HBV efficacy of the antibodies induced by CR-474 
T3-SEQ13 in cynomolgus monkeys, polyclonal antibodies were purified from sera from 475 
the immunized monkeys. We measured the anti-HBs titers of the purified polyclonal 476 
antibodies and diluted them to 10 IU/mL, which was equivalent to the HBIG titer. The 477 
same amount of polyclonal anti-CR-T3-SEQ13 antibodies and HBIG (10 IU/mL, 1 mL) 478 
was injected into the HBV-Tg mice. Both the anti-CR-T3-SEQ13 polyclonal antibodies 479 
and HBIG significantly reduced the serum HBsAg levels in the mice (Figure 7C). The 480 
serum HBsAg was more significantly reduced in the mice in the anti-CR-T3-SEQ13 481 
treatment group than in those in the HBIG group, and the duration of suppression was 482 
also longer in the anti-CR-T3-SEQ13 treatment group. The results indicated that the 483 
antibodies induced by CR-T3-SEQ13 in cynomolgus monkeys could potently mediate 484 
clearance of HBsAg, which also suggested that the main mechanism of CR-T3-SEQ13 485 
treatment was to induce anti-HBsAg specific antibody responses and mediate 486 
clearance of HBsAg. 487 
 488 
DISCUSSION  489 
Dozens of pre-clinical and clinical efforts have been failed to generate an effective 490 
therapeutic vaccine against chronic hepatitis B20, indicating that it is indeed difficult to 491 
overcome immune tolerance in patients with chronic hepatitis B, and it is particularly 492 
difficult to produce an anti-HBs antibody response that can mediate HBsAg clearance. 493 
In this study, we constructed a virus-like particle displaying the candidate epitope 494 
based on a B cell epitope (HBsAg-aa119-125) that was recognized by the superior 495 
candidate therapeutic antibody E6F6 described in our previous study24. First, we used 496 
HBC149 as an epitope-displaying carrier and HBV-Tg mice to screen the candidate 497 
molecules. A total of 23 epitope peptides in the hydrophilic region of HBsAg were 498 
prepared and evaluated, and finally the optimized epitope SEQ13 was obtained. 499 
Although HBC-SEQ13 could induce an anti-HBs response and suppressed HBsAg 500 
significantly in the female HBV-Tg mice, it did not function effectively in the male HBV-501 
Tg mice. As a vaccine based on a B cell epitope, the carrier protein should be another 502 
crucial factor in achieving a strong immune response. Therefore, we tested dozens of 503 
carriers. Finally, in this study, we used a carrier derived from the capsid of a bat 504 
hepatitis B virus. The therapeutic effects of the molecule displayed by SEQ13 on the 505 
roundleaf bat HBV core (RBHBcAg149) was greatly improved and effectively inhibited 506 
the HBsAg level in the male HBV-Tg mice. To further optimize the RBHBcAg149 507 
carrier, one human CTL epitope and two helper T cell epitopes were introduced by 508 
replacement to obtain the candidate molecule CR-T3-SEQ13 (Figure 1). 509 
CR-T3-SEQ13 induced a specific antibody response to the SEQ13 epitope in the 510 
HBV carrier mice and significantly inhibited HBsAg and HBV DNA in the HBV-Tg mice 511 
in a dose-dependent manner (Figure 3). In contrast, the vaccine based on HBsAg plus 512 
HBcAg did not exhibit a significant inhibitory effect on viral antigens (Supplemental 513 
Figure 3). The efficacy of the vaccine used alone or in combination with first-line anti-514 
HBV drugs was evaluated. The inhibitory effect on HBsAg was slightly better in the 515 
CR-T3-SEQ13 + TDF (Figure 6A-D) or CR-T3-SEQ13 + interferon-a (Supplemental 516 
Figure 7) treatment regimen, although the difference was not statistically significant. 517 
In the acquired immune tolerant HDI-HBV model, CR-T3-SEQ13 vaccination inhibited 518 
HBsAg to a level below the detection limit for more than 40 weeks (Figure 5). The 519 
serological markers were similar to those of a functional cure. In the nonhuman 520 
primate model, we demonstrated that CR-T3-SEQ13 had excellent immunogenicity 521 
and could induce cynomolgus monkeys to produce high-titer sA epitope antibodies, 522 
which could neutralize HBV infection in the HepG2-NTCP cell model in vitro and 523 
effectively eliminate HBsAg by passive transfer to HBV-Tg mice (Figure 7). Anti-524 
SEQ13 polyclonal antibodies from BALB/c mice suppressed HBsAg in vivo with broad-525 
spectrum activity (Figure 2C). Consistently, the anti-HBV effects of CR-T3-SEQ13 526 
were positively correlated with the anti-SEQ13 antibody titer (Figure 5E-F). These data 527 
indicated that the major mechanism of CR-T3-SEQ13 treatment was dependent on 528 
the induction of anti-SEQ13 antibodies, which mediated clearance of HBsAg-529 
containing viral particles.  530 
A comparison for adjuvants and delivery routes is important for development of a 531 
therapeutic vaccine, thus we performed experiments to find the potential adjuvants 532 
and superior routes. Various adjuvants, including Addavax, Quil-A, Chitosan, ODN 533 
1585, ODN 1826 and conventional alum adjuvant (Supplemental figure 8 A), were 534 
evaluated in wild type C57BL/6 mice and HBV-TG mice, the data showed that the 535 
immunogenicity and efficacy of vaccine formulated with Addavax is comparable with 536 
alum adjuvant, both of which were better than the other adjuvants (Supplemental 537 
figure 8 B, C). We also compared three different delivery routes, including 538 
intramuscular injection (I.M.), intravenous injection (I.V.) and subcutaneous injection, 539 
the data showed that the efficacy of I.M. and subcutaneous injection were comparable, 540 
both of which were much better than I.V. (Supplemental figure 9), we think it is because 541 
of that antigen injected by I.V. would be cleared rapidly in the peripheral circulating 542 
blood. 543 
Although CR-T3-SEQ13 could induce antibodies that efficiently mediate HBsAg 544 
clearance in HBV carrier mice, thus suppressing HBsAg levels and sustaining for a 545 
long period of time, has the potential to restore HBV-specific immune responses, but 546 
the mouse models do not equal to chronic hepatitis B patients, they have different 547 
immune status against HBV and also different sensitivity to vaccination immune 548 
response. Therefore, we are unable to accurately predict what will happen in the 549 
patients based on the results obtained in the mouse models. In addition, since SEQ13 550 
only contains a part of the B cell epitope of HBsAg, the induced antibody diversity 551 
might be relatively limited, which may face problems such as virus escape mutation or 552 
weak antibody responses. All of these challenges have to be verified in clinical trials. 553 
Much evidence has indicated that the appearance of T cell exhaustion is highly 554 
associated with the pathogen burden of the host11, 36. Removal of circulating HBsAg 555 
by anti-HBs antibody in HBV carrier mice could gradually reduce tolerance and 556 
enhance subsequent therapeutic vaccination13. Furthermore, data from the treatment 557 
cohort of chronic hepatitis B patients also showed that HBV-specific T cell responses 558 
were negatively correlated with the HBsAg level37. Consistently, clinical trial data for 559 
REP-2139 support the hypothesis that long-term suppression of HBsAg can promote 560 
HBsAg-specific B cell responses14, 38.  561 
Therefore, suppressing the high level of circulating HBsAg should be a key factor 562 
for immunotherapy of chronic hepatitis B23. Combination of approaches that show 563 
efficient reduction of HBsAg have chance to restore the effective immune response 564 
against HBV. The viral antigens reducing treatments, such as therapeutic antibody, 565 
siRNA or NAPs, may benefit for induction of humoral responses by therapeutic vaccine. 566 
This strategy will hopefully overcome immune tolerance in chronic hepatitis B patients 567 
and allow the clinical efficacy of a therapeutic vaccination to cure HBV infection. 568 
Taken together, our data show that CR-T3-SEQ13 is a superior candidate for 569 
further development towards a therapeutic vaccine for CHB treatment. Our findings 570 
provide new insights into understanding the approach of a therapeutic vaccine based 571 
on B cell epitopes against persistent viral infection. Considering the distinct anti-HBV 572 
effects provided by the CR-T3-SEQ13 with alum/another novel adjuvant-based 573 
therapeutic vaccine alone or in combination with interferon or nucleos(t)ide analogues, 574 
other anti-HBV candidates under development may provide promising strategies to 575 
promote the HBV cure. 576 
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  693 
Figure legends 694 
Figure 1. Construction of a unique B cell epitope based virus-like particulate antigen: 695 
CR-T3-SEQ13. (A) Schematic diagram of the design from RBHBcAg to CR-T3-SEQ13; 696 
RBHBcAg-aa150-189 was truncated, HBcAg-aa18-27, HBcAg-aa50-69 and HBcAg-697 
aa120-140 were introduced into the RBHBcAg149 by homologous replacement, 698 
sequence of SEQ13 polypeptide and linker was inserted by replacement of RBHBcAg-699 
aa79-81, forming a chimeric molecule with a length of 193 amino acid, designated CR-700 
T3-SEQ13. (B) Coomassie blue staining of SDS-PAGE and (C) EM picture of 701 
recombinant CR-T3-SEQ13 protein. (D) Cyro-EM structure of CR-T3-SEQ13 particle, 702 
SEQ13 epitopes are displayed on the spikes of particle. 703 
 704 
Figure 2. CR-T3-SEQ13 induces sA epitope-specific antibodies with broad-spectrum 705 
activity to mediate HBsAg clearance. (A) The kinetics of Anti-HBs antibody response 706 
level in BALB/c mice immunized with a series of vaccine formulations containing fixed 707 
alum adjuvant dose (840 μg/mL) and different antigen doses, including 60 μg, 30 μg, 708 
12 μg, 6 μg, 3 μg, 0.6 μg, and 0 μg, respectively. (B) Alanine scanning epitope mapping 709 
strategy was used to identify the key residues for binding activity of polyclonal 710 
antiserum or monoclonal antibodies derived from mice, rabbits and cynomolgus 711 
monkeys that immunized with CR-T3-SEQ13. The value means the fold change of 712 
binding activity caused by each amino acid mutation. (C) The dynamic change of 713 
HBsAg levels in the four genotypes of HBV carrier mice after treatment with polyclonal 714 
antiserum derived from BALB/c mice immunized with CR-T3-SEQ13. The data 715 
represent mean ± SEM, N=4. Significant differences between groups are indicated on 716 
the top. ****P < 0.0001; two-tailed unpaired t-tests. 717 
 718 
Figure 3. CR-T3-SEQ13 can significantly inhibit HBsAg and HBV DNA in HBV 719 
transgenic mice in a dose-dependent manner and sustain the suppression effects for 720 
a long time. (A-D) HBV transgenic mice were intramuscular injected with vaccine 721 
formulations containing fixed alum adjuvant dose (840 μg/mL) and different antigen 722 
doses, including 30 μg, 12 μg and 3 μg and 0 μg, respectively. A total of 6 doses were 723 
injected at 0, 2, 3, 4, 5 and 6 weeks. (A) Dynamics of HBsAg level in female HBV-Tg 724 
mice; (B) Dynamics of HBsAg level in male HBV-Tg mice; (C) Dynamics of HBV DNA 725 
level in female HBV-Tg mice; (D) Dynamics of HBV DNA level in male HBV-Tg mice. 726 
(E-F) HBV-Tg mice were injected with vaccine formulations containing 840 μg/mL of 727 
alum adjuvant and 12 μg of CR-T3-SEQ13 at 0, 2, 3, 4, 5 and 6 weeks and 0, 2, 4, 6, 728 
8, 10 weeks, respectively. (E) Dynamics of HBsAg level in female HBV-Tg mice 729 
vaccinated by different schedule; (B) Dynamics of HBsAg level in male HBV-Tg mice 730 
vaccinated by different schedule. The data represent mean ± SEM, N=4. 731 
 732 
Figure 4. Immunohistochemical staining of HBsAg and HBcAg in the livers of HBV-Tg 733 
mice (N=4) after CR-T3-SEQ13 treatment. Assays were performed at week 8 after 734 
treatment. The scale bar is 20 μm.  735 
 736 
Figure 5. CR-T3-SEQ13 vaccination could eradicate HBsAg and HBV DNA in 737 
hydrodynamic injection-based HBV carrier mice. A total of five doses of CR-T3-SEQ13 738 
were injected at week 0, 2, 3, 4 and 5, respectively. (A) Dynamics of HBsAg level and 739 
(B) kinetics of Anti-HBs antibody level in HDI-HBV carrier mice (Genotype A, N=5). 740 
The data represent mean ± SEM. 741 
Figure 6. Combinational therapy with CR-T3-SEQ13 plus nucleoside analogues. HBV 742 
transgenic mice were treated with TDF alone, ETV alone, CR-T3-SEQ13 alone, CR-743 
T3-SEQ13plus ETV and CR-T3-SEQ13 plus TDF. In the combinational therapy group, 744 
two weeks after oral administration of the analogues, the CR-T3-SEQ13 was injected 745 
at Week 0, 2, 3, 4, 5, 6. Dynamics change of serum HBsAg levels in (A) Male and (B) 746 
Female HBV-Tg mice, and HBV DNA levels in (C) Male and (D) Female HBV-Tg mice. 747 
(E) The correlation between HBsAg decline and Anti-SEQ13 antibody titer in female 748 
mice treated with CR-T3-SEQ13, TDF plus CR-T3-SEQ13 and ETV plus CR-T3-749 
SEQ13. (F) The correlation between HBsAg decline and Anti-SEQ13 antibody titer in 750 
female mice treated with CR-T3-SEQ13, TDF plus CR-T3-SEQ13 and ETV plus CR-751 
T3-SEQ13. Data are presented as mean ± SEM, N=4. The arrow refers to injection of 752 
CR-T3-SEQ13 and the green band refers to nucleotide analogue. ETV=Entecavir; 753 
TDF= Tenofovir disoproxil fumarate.  754 
 755 
Figure 7. Immunogenicity of CR-T3-SEQ13 in Cynomolgus Monkeys and potency of 756 
antiserum. (A) The kinetics of Anti-HBs antibody titer in monkeys immunized with CR-757 
T3-SEQ13 vaccine and alum control. 2 male and 2 female monkeys received 1 758 
mL/dose of formulation containing CR-T3-SEQ13 (20 μg/dose) and alum adjuvant 759 
(420 μg/mL), by IM injection in the deltoid muscle of the upper arm. The control group 760 
(2 male and 1 female monkey) received alum adjuvant only. The immunization 761 
schedule was 6 injections over the time course of 0, 2, 6, 10, 14 and 18 weeks. (B) In 762 
vitro neutralizing activity of serum derived from monkeys vaccinated with CR-T3-763 
SEQ13, HBIG (1 IU/mL) was used as control group. (C) Serum HBsAg dynamics of 764 
HBV-Tg mice after infusions of polyclonal antibodies (pAb). CR-T3-SEQ13 pAb and 765 
HBIG were injected into HBV-Tg mice (N=4) at the same dosage (10 IU/dose). 766 
Untreated mice served as controls. The data were expressed as the mean±SEM. 767 
HBIG = Human Hepatitis B Immunoglobulin. 768 
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Supplemental figure 1. Chimeric Virus-like particles (VLPs) displaying sA-
epitopes. (A) Schematic constructs of HBC149-sA epitope, sA-epitopes with 
two-sided linkers (GGGGSGGGGS) are inserted into HBC149 between aa78 
and aa82 of HBcAg. (B) SDS-PAGE analysis of purified recombinant proteins 
and EM picture of recombinant VLPs, including HBC149 carrier displaying 
HBsAg-aa119-125, HBsAg-aa113-127, HBsAg-aa115-125, HBsAg-aa113-135, 
HBsAg-aa111-148 and carrier control.  
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Supplemental figure 2. Evaluation of immunogenicity and antiviral effects of 
VLPs displaying peptides containing HBsAg-aa119-125. Kinetics of (A) Anti-
HBs and (B) Anti-carrier antibody titers in BALB/c mice immunized with sA 
epitope based vaccine, four doses of vaccine were injected at 0, 2, 4 and 6 
week, respectively. Kinetics of (C) Anti-HBs and (D) Anti-carrier antibody titers 
in HBV-Tg mice treated with sA epitope based vaccine, 5 doses of vaccine were 
injected at week 0, 2, 3, 4 and 5, respectively. Dynamic change of the levels of 
(E) HBsAg and (F) HBV DNA in HBV-Tg mice vaccinated with VLPs displaying 
peptides containing HBsAg-aa119-125. The data were expressed as the 
mean±SEM, N=4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental figure 3. Comparison of characteristics and function of CR-T3-
SEQ13 and CR-SEQ13. (A) Negative staining electron microscopy picture of 
recombinant VLPs of CR-T3-SEQ13 and CR-SEQ13. (B) Dynamic change of 
HBsAg levels in HBV-Tg mice (N=4, up right panel for male, lower right panel 
for female) treated with CR-T3-SEQ13 and CR-SEQ13 by the same dosage 
and schedule, respectively. (C) Comparison of whole-blood interferon gamma 
responses to CR-T3-SEQ13, CR-SEQ13 and negative buffer control. Whole 
blood were derived from 25 chronic hepatitis B patients, IFNγ release assay 
(IGRA) was performed as described in methods. The data were expressed as 
the mean±SEM. Two-sided, unpaired t-test was used. Statistical significance 
was defined as *P < 0.05; **P < 0.01. 
 
 
Supplemental figure 4. Comparison of antiviral effects of CR-T3-SEQ13 
vaccine and HBsAg & HBcAg vaccine. Dynamic change of (A) HBsAg and (B) 
HBV DNA levels in HBV-Tg mice (N=4) treated with CR-T3-SEQ13 vaccine or 
HBsAg & HBcAg vaccine. The data were expressed as the mean±SEM. Two-
sided, unpaired t-test was used. Statistical significance was defined as *P < 
0.05; **P < 0.01. Recombinant HBsAg derived from CHO cells HBcAg derived 
from E.Coli were purchased from Beijing Wantai Biological Pharmacy 
Enterprise Co., Ltd. 
 
 
 
 
 
  
Supplemental figure 5. Quantitative analyses for HBsAg (left panel) and 
HBcAg (right panel) in the specimens of liver tissue lysates derived from HBV-
Tg mice (Genotype A, N=4) that after CR-T3-SEQ13 treatment. Mice were 
sacrificed at week 8 after treatment. The data were expressed as the 
mean±SEM. p Values were calculated using a two-sided unpaired t test, and 
***indicated p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental figure 6. Kinetics of anti-SEQ13 antibody titers in (A) Male and 
(B) Female HBV-Tg mice. HBV transgenic mice were treated with TDF alone, 
ETV alone, CR-T3-SEQ13 alone, CR-T3-SEQ13plus ETV and CR-T3-SEQ13 
plus TDF. In the combinational therapy group, two weeks after oral 
administration of the analogues, the CR-T3-SEQ13 was injected at Week 0, 2, 
3, 4, 5, 6. Data are presented as mean ± SEM, N=4. The arrow refers to 
injection of CR-T3-SEQ13. ETV=Entecavir; TDF= Tenofovir disoproxil fumarate. 
 
  
  
Supplemental figure 7. Dynamics change of serum HBsAg levels in male 
HBV-Tg mice treated with mIFN-a alone, CR-T3-SEQ13 alone and CR-T3-
SEQ13 plus mIFN-a. In the mIFN-a group and combinational therapy group, 
300000 unit/dose of mIFN-a was given by subcutaneous injection every two 
days between week0-6; in the CR-T3-SEQ13 group and combinational therapy 
group, CR-T3-SEQ13 was injected at week 0, 2, 3, 4, 5, 6. Data are presented 
as mean ± SEM, N=4. The arrow refers to injection of CR-T3-SEQ13 and the 
green band refers to mIFN-a. 
 
 
Supplemental figure 8. Comparison of the effects of CR-T3-SEQ13 vaccine 
formulations containing different adjuvants (A) Brief information of adjuvants 
used in this study, except for the alum adjuvant was prepared in our lab, the 
other five adjuvants were purchased from InvivoGen. (B) Comparison of the 
anti-HBsAg antibody titer induced CR-T3-SEQ13 formulated with different 
adjuvants. Each dose of formulation contain 1.2 µg of CR-T3-SEQ13 antigen 
and determined dose of adjuvant that listed in the table A. C57BL/6 mice (N=7) 
were immunized with 6 doses of vaccine at week 0, 2, 3, 4, 5 and 6, respectively. 
(C) Dynamics of HBsAg levels in female HBV-Tg mice treated by CR-T3-
SEQ13 formulated with different adjuvants. Each dose of formulation contain 
12 µg of CR-T3-SEQ13 antigen and determined dose of adjuvant that listed in 
the table A. HBV-Tg mice mice (N=4) were immunized with 6 doses of vaccine 
at week 0, 2, 3, 4, 5 and 6, respectively. The data were expressed as the 
mean±SEM.  
 
 
 
 
 
 
 
 
 Supplemental figure 9. Comparison of the effects of CR-T3-SEQ13 vaccine 
by different delivery routes. Dynamic change of HBsAg levels in female HBV-
Tg mice (Genotype A, N=4) treated with CR-T3-SEQ13 by intramuscular 
injection, subcutaneous injection and intravenous injection. The data were 
expressed as the mean±SEM.  
 
 
 
 
 
 
 
 
 
 
 
 Supplemental figure 10. Dynamic change of HBsAg levels in HBV-Tg mice 
(Genotype A, N=4) treated by single dose of CR-T3-SEQ13 vaccine. The data 
were expressed as the mean±SEM. 
 
Supplemental Materials and Methods 
Vaccine preparation 
To produce the chimeric particulate antigens displaying the sA epitopes 
(HBC-S119-125, HBC-S113-127, HBC-S115-125, HBC-S113-135 and HBC-
S111-148), the coding sequences of these peptides were cloned into the 
pC149/mut vector1 by annealing oligos ordered from Sangon Biotech 
(Shanghai) Co., Ltd. (Supplemental Table 1). The expression and purification 
of these proteins were similar to those of pC149/mut1. The antigens were mixed 
with alum adjuvant following the previously described protocol2. 
The CR-T3-SEQ13 gene fragment was synthesized by GENEWIZ, Inc. 
(Suzhou, China). The gene was cloned into the pTO-T7 expression vector, 
which was constructed in our lab3; correct plasmids expressing CR-T3-SEQ13 
were transformed into E. coli strain ER25661. The CR-T3-SEQ13 protein and 
vaccine formulation used in this study were provided by our partner, Xiamen 
Innovax Biotech Co., Ltd.  
Epitope mapping of antibodies induced by CR-T3-SEQ13 
Design and synthesis of peptides. The alanine scanning epitope mapping 
strategy was used to identify key residues for antibody binding. Alanine was 
introduced for each residue of HBs-aa117-132; the peptides were synthesized 
by Xiamen Jingju Technology Co., Ltd. (Supplemental Table 2). 
Polyclonal antisera and mAbs against CR-T3-SEQ13. The sera were 
collected from the CR-T3-SEQ13-immunized mice, rabbits and cynomolgus 
monkeys for analysis of the characteristics of the polyclonal antibodies induced 
by CR-T3-SEQ13. The mAbs were obtained from immunized BALB/c mice 
using standard mouse hybridoma technology4 and screened by ELISA using 
CHO-HBsAg-coated 96-well plates (Beijing Wantai Biological Pharmacy 
Enterprise Co., Ltd.). 
ELISA. The peptides were coated onto 96-well plates at a concentration of 
100 ng/well. The binding activities of the polyclonal sera and mAbs were 
detected by indirect ELISA, and serial dilutions were prepared to find a proper 
concentration of samples that bound to SEQ13-WT with a readout OD value 
(OD450nm-OD630nm) that ranged from 1.0 to 2.0. Then, the fold change in the 
binding activity caused by each mutation was calculated as follows: 
ODmut/ODWT–1. Finally, a heatmap was created using GraphPad Prism 7. 
Detection of HBV markers  
The HBV DNA levels in the mouse serum specimens were measured using 
a real-time qPCR assay from Premix Ex Taq™ (Takara, Dalian, China). The 
primer sequences were 5’-TTTCACCTCTGCCTAATCAT-3’ and 5’-
TCAGAAGGCAAAAAAGAGAGTAACTC-3’. The probe sequence was 5’-Hex-
CCTTGGGTGGCTTTGGGGCATGGA -1-3’.  
The HBsAg chemiluminescent quantitation kit and HBeAg quantitation 
ELISA kit were purchased from Beijing Wantai Biological Pharmacy Enterprise 
Co., Ltd. The anti-HBs and anti-carrier titers were detected using indirect ELISA 
kits developed by Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 
For the immunohistochemistry assay, mouse livers were fixed in formalin 
(3.7% formaldehyde in PBS) for analysis. Intrahepatic HBsAg and HBcAg were 
detected using immunohistochemical staining with the anti-HBsAg mAb 83H12 
in our lab and polyclonal rabbit anti-HBcAg (DAKO, B058601), respectively. The 
MaxVisionTM HRP-Polymer IHC Kit (Maixin, Fuzhou, China) was used. 
Detection of Anti-HBs and Anti-SEQ13 antibody by indirect ELISA 
The titers of anti-HBs and anti-SEQ13 were measured by indirect ELISA.  
Wells were coated with the recombinant HBsAg protein (CHO cell-derived, 
Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) or synthesized 
SEQ13 peptide (Jingju, Xiamen, China) at 200 ng per well, and nonspecific 
binding was blocked with phosphate-buffered saline (PBS) that contained 2% 
bovine serum albumin (BSA) and 10% sucrose. A series of 5-fold series 
dilutions of serum that ranged from 50-6250 were prepared. For the test, 100 
μl of specimens were added to the reaction well and incubated for 60 minutes 
at 37°C, followed by washing and reaction with horseradish peroxidase (HRP)-
conjugated anti-mouse pAb (Thermo Scientific, Rockford, USA). After reaction 
of chromogenic substrate and stop solution, read the absorbance of each well 
at 450 nm and 630 nm. The maximum dilution fold that yield (OD450 nm- 630 
nm)>0.1 will be used to calculate the antibody, titer=(OD450 nm- 630 nm)/0.1
×dilution fold. 
Cryo-EM and three-dimensional (3D) reconstruction of CR-T3-SEQ13 
An aliquot of a 3 μL purified CR-T3-SEQ13 sample (3mg/mL) was deposited 
onto a glow discharged Quantifoil holey carbon grid (R2/2, 200 mesh, Quantifoil 
Micro Tools). After 6 s blotting to remove extra sample, the grid was plunge-
frozen into liquid ethane using a FEI Vitrobot. A total of 1704 cryo-EM images 
were recorded on an FEI Falcon II direct detector camera at 93,000 nominal 
magnification in an FEI TF30 microscope at 300 kV, with defocus settings 
determined to be between 0.8 and 3.2 μm using GCTF5, and with an electron 
dose of ~25 e/Å2. Particles were then manually picked with the program 
Eman26. The origin and orientation parameters for each of these particle 
images were estimated by means of model-based procedures and an initial 
model was generated with the random model method7. After several rounds of 
reference-free 2D and 3D classifications using Relion2.08. 5886 good particles 
were selected for final 3D refinement with Relion2.0. The map resolution was 
determined based on gold standard criteria of 0.143 FSC cutoff9. Figures were 
prepared with UCSF Chimera10. 
Combinational treatment experiments 
The treatment groups included (1) ETV alone, (2) TDF alone, (3) CR-T3-
SEQ13 alone, (4) ETV plus CR-T3-SEQ13, and (5) TDF plus CR-T3-SEQ13. 
The anti-HBV effects of these five regimens were assessed in the HBV-Tg 
mouse model. HBV-Tg mice were selected at 8 weeks of age, and 4 female 
and 4 male mice per group were treated as per the corresponding regimen. 
ETV or TDF powder was administered orally in the drinking water of the mice 
(water consumption was calculated as 5 mL per day for each mouse). The 
average ETV dosage was 3.2 mg/kg/day, and the average TDF dosage was 
100 mg/kg/day. Two weeks after oral administration of the analogues, CR-T3-
SEQ13 was injected via the lateral muscles of the hind limbs. According to the 
immunization schedule, CR-T3-SEQ13 was given at weeks 0, 2, 3, 4, 5, and 6. 
The starting time point of the HBV injection was deemed week 0. The blood 
collection time points used to monitor the serum HBsAg and HBV DNA levels 
in the mice were days -14, -9, -6, and -3 and weeks 0, 1, 2, 3, 4, 5, 6, 7, and 8.   
In vivo potency of anti-CR-T3-SEQ13 sera or purified polyclonal IgG  
To evaluate the broad spectrum anti-HBV efficacy of the polyclonal 
antibodies induced by CR-T3-SEQ13, sera from BALB/c mice immunized with 
CR-T3-SEQ13 were collected according to the following procedure. Twenty 
BALB/c mice were immunized with CR-T3-SEQ13 (12 μg/dose, a total of 6 
injections) and sacrificed at week 8. To construct HBV carrier mice carrying 
HBV genotypes A, B, C and D, HBV replicon plasmids of the four predominant 
HBV genotypes were transferred into the livers of BALB/c mice by 
hydrodynamic injection through the tail vein. Then, the sera from the immunized 
BALB/c mice containing the polyclonal anti-CR-T3-SEQ13 Abs were injected 
via the tail vein (250 μL per mouse) into the HBV carrier mice for each of the 
four genotypes tested. Orbital blood was collected pretreatment (0) and at 2 
and 12 hours posttreatment, and short-term dynamic changes in the HBsAg 
levels were monitored. 
To further evaluate the in vivo anti-HBV efficacy of the antibodies induced 
by CR-T3-SEQ13 in cynomolgus monkeys, the resultant antibodies were 
purified from sera from immunized cynomolgus monkeys. Protein G medium 
was used to purify IgG polyclonal antibodies, and an indirect ELISA was 
performed to test the anti-HBs binding activity of the polyclonal antibodies. The 
activity was calibrated to a level equivalent to that of commercial HBIG (Sichuan 
Yuanda Shuyang Pharmaceutical Co., Ltd.). The binding titer of the monkey 
serum polyclonal antibodies obtained by purification in this experiment was 
equivalent to 10 IU/mL of HBIG. Purified polyclonal anti-CR-T3-SEQ13 
antibodies or HBIG (1 mL) were injected into the HBV-Tg mice via the tail vein. 
Blood was collected at 12 h, 24 h, 2 d, 3 d, 4 d and 6 d post injection to monitor 
changes in the serum HBsAg levels in the mice. 
In vitro neutralizing assay 
A HepG2-NTCP cell line that supported HBV infection was generated by a 
sleeping-beauty transposon-based system with co-expression of the 
fluorescent protein mCherry and puromycin via all-in-one plasmid transfection11. 
The supernatant was collected from the HepAD3812 cells and concentrated by 
ultracentrifugation, and the HBV inoculum was quantified by real-time PCR. For 
the HBV infection neutralization assay, a two-fold dilution gradient was created 
from 1/10 to 1/10240 for both the monkey antiserum and HBIG (1 IU/mL); then, 
the dilutions were mixed with the HBV inoculum and incubated for 1 hour at 
37°C. The cells were infected with a 300-µL mixture supplemented with 4% 
polyethylene glycol 8000 and 2% DMSO; approximately 200 VEG/cell of HBV 
was used. The cultures were incubated overnight, and then the cells were 
gently washed three times with 1x phosphate-buffered saline (PBS) and 
cultured for an additional 6 days. To measure HBV infection, HBeAg in the 
culture supernatants was detected at day 6 using an HBeAg ELISA kit. 
Statistical analysis 
All experimental data are presented as the mean ± SEM. A two-sided, 
unpaired t-test was used. Statistical significance was defined as *P < 0.05, **P 
< 0.01, ***P < 0.001, and ****P < 0.0001. Significance is indicated in the figures. 
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Table S1 Primers for construction of HBsAg-aa119-125 containing HBC149-sA-epitopes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Sequence 
S119-
125F 
GATCCGGACCATGCAAAACCTGCACGG 
S119-
125R 
AATTCCGTGCAGGTTTTGCATGGTCCG 
S113-
127F 
GATCCTCAACAACAACCAGTACGGGACCATGCAAAACCTGCACGACTCCTG 
S113-
127R 
AATTCAGGAGTCGTGCAGGTTTTGCATGGTCCCGTACTGGTTGTTGTTGAG 
S115-
125F 
GATCCACAACCAGTACGGGACCATGCAAAACCTGCACGG 
S115-
125R 
AATTCCGTGCAGGTTTTGCATGGTCCCGTACTGGTTGTG 
S113-
135F 
GATCCTCATCAACAACCAGCACCGGACCATGCAAAACCTGCACAACTCCTGCTCAAGGA
ACCTCTATGTTTCCCG 
S113-
135R 
AATTCGGGAAACATAGAGGTTCCTTGAGCAGGAGTTGTGCAGGTTTTGCATGGTCCGGT
GCTGGTTGTTGATGAG 
S111-
148F 
GGATCCCCAGGATCATCAACAACCAGCACCGGACCATGCAAAACCTGCACAACTCCTGC
TCAAGGAACCTCTATG 
S111-
148R 
GAATTCGGTGCAGTTTCCGTCCGTAGGTTTTGTACAGCAACATGAGGGAAACATAGAGG
TTCCTTGAGCAG 
Table S2 Amino acid sequence of mutated SEQ13 peptides 
 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 
SEQ13-
S117A S S T T A T G P C K T C T T P A Q G T S M F P 
SEQ13-
T118A S S T T S A G P C K T C T T P A Q G T S M F P 
SEQ13-
G119A S S T T S T A P C K T C T T P A Q G T S M F P 
SEQ13-
P120A S S T T S T G A C K T C T T P A Q G T S M F P 
SEQ13-
C121S S S T T S T G P S K T C T T P A Q G T S M F P 
SEQ13-
K122A S S T T S T G P C A T C T T P A Q G T S M F P 
SEQ13-
T123A S S T T S T G P C K A C T T P A Q G T S M F P 
SEQ13-
C124S S S T T S T G P C K T S T T P A Q G T S M F P 
SEQ13-
T125A S S T T S T G P C K T C A T P A Q G T S M F P 
SEQ13-
T126A S S T T S T G P C K T C T A P A Q G T S M F P 
SEQ13-
P127A S S T T S T G P C K T C T T A A Q G T S M F P 
SEQ13-
Q129A S S T T S T G P C K T C T T P A A G T S M F P 
SEQ13-
T131A S S T T S T G P C K T C T T P A Q G A S M F P 
SEQ13-
S132A S S T T S T G P C K T C T T P A Q G T A M F P 
SEQ13-
WT S S T T S T G P C K T C T T P A Q G T S M F P 
 
